Biopharmaceutical company Navidea Biopharmaceuticals Inc (NYSE American:NAVB) Friday disclosed an extension of the Lymphoseek patent, which has been assigned US patent 6,409,990, for an additional five years.
The US Food and Drug Administration (FDA) has reportedly released a letter indicating that the US Patent and Trademark Office (USPTO) is allowed to extend Lymphoseek's patent for an additional five years or until 12 May 2025.
In conjunction, the patent claims Lymphoseek (technetium (Tc 99m) tilmanocept) has been exclusively licensed with varying geographical and medical indication coverages to Cardinal Health and Navidea.
Following the allowance of this patent extension, Cardinal Health and Navidea will extend their exclusive rights to manufacture and commercialise Lymphoseek until the end of the extended patent term in 2025.
Emmaus Life Sciences' Endari label enhancements receive US FDA approval
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma